Ophthalmology Deal Benchmarks
Benchmark licensing terms for age-related macular degeneration, glaucoma, dry eye disease, and retinal gene therapy. Ophthalmology deals are driven by high unmet need and premium pricing in retinal diseases. Benchmarks derived from 201 verified transactions.
201
Total Deals
$668M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
97
license
53
acquisition
29
collaboration
16
option
4
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Sydnexis, Inc. → Ligand Pharmaceuticals Inc. Ryjunea | license | $23M | $23M | Sep 2026 |
Sydnexis → Ligand Ryjunea | acquisition | $23M | $23M | Sep 2026 |
Sydnexis → Ligand Pharmaceuticals Ryjunea (royalty and milestone interest from Sydnexis-Santen license, EMEA) | acquisition | $23M | — | Sep 2026 |
Alkeus Pharmaceuticals → Tarsus gildeuretinol | acquisition | $450M | $800M | Aug 2026 |
Accure Therapeutics → Oculis Holding AG Privosegtor | acquisition | $4M | — | Aug 2026 |
Accure Therapeutics → Oculis Privosegtor (ACT-01) and ACT-02 | acquisition | $4M | — | Aug 2026 |
Viatris → Harrow Tyrvaya | acquisition | $30M | $100M | Aug 2026 |
Alkeus Pharmaceuticals → Tarsus Pharmaceuticals Gildeuretinol acetate (ALK-001) | acquisition | $450M | $800M | Aug 2026 |
iRenix Medical, Inc. → Tarsus Pharmaceuticals, Inc. IRX-101 | acquisition | $75M | $565M | Jul 2026 |
Apellis Pharmaceuticals → Biogen Empaveli (pegcetacoplan) / SYFOVRE (pegcetacoplan intravitreal) | acquisition | $5.6B | $6.1B | Jun 2026 |
Benchmark Your Ophthalmology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 201 verified ophthalmology transactions.
Ophthalmology Deal Benchmarking FAQ
What drives premium valuations in retinal disease deals?
Retinal disease deals (AMD, diabetic macular edema, geographic atrophy) command premium valuations due to the large addressable market ($15B+ globally), premium pricing ($10K-$20K+ per injection), and long duration of treatment. Gene therapy approaches for inherited retinal diseases add further upside with potential one-time curative pricing.
How are ophthalmology drug delivery deals structured?
Ocular drug delivery platform deals (sustained-release implants, port delivery systems, suprachoroidal injection) are structured as platform licenses with multiple product options. Upfronts range $30M-$150M with per-product milestones and royalties. These deals often include co-development provisions where the platform owner retains manufacturing rights.
What are typical royalty rates for ophthalmology licensing deals?
Ophthalmology royalties typically range 12-22% for retinal products and 8-15% for anterior segment (glaucoma, dry eye). Anti-VEGF biosimilars and next-gen competitors have compressed royalty expectations for AMD, while novel mechanisms (complement inhibitors, gene therapy) still command premium rates above 18%.